Antiplatelet Medications

Old and Emerging Therapies

William M. Stone, Sailendra Naidu, Alyssa Chapital, Samuel R. Money

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Antiplatelet medications have been proven to enhance outcomes in patients with cardiovascular disease. The ideal platelet inhibitor would be quick and reversible and would have universal response, an excellent safety profile, and proven benefit. Currently available antiplatelet medications have been demonstrated to have variable patient response. In light of this medication resistance, emerging therapies to inhibit platelet aggregation are under investigation. We review the currently available antiplatelet medications and the current state of these emerging therapies.

Original languageEnglish (US)
Pages (from-to)140-148
Number of pages9
JournalAnnals of Vascular Surgery
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Platelet Aggregation Inhibitors
Platelet Aggregation
Cardiovascular Diseases
Safety
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Antiplatelet Medications : Old and Emerging Therapies. / Stone, William M.; Naidu, Sailendra; Chapital, Alyssa; Money, Samuel R.

In: Annals of Vascular Surgery, Vol. 24, No. 1, 01.01.2010, p. 140-148.

Research output: Contribution to journalReview article

Stone, William M. ; Naidu, Sailendra ; Chapital, Alyssa ; Money, Samuel R. / Antiplatelet Medications : Old and Emerging Therapies. In: Annals of Vascular Surgery. 2010 ; Vol. 24, No. 1. pp. 140-148.
@article{54845187c80e42e09ae5faf89cd42ae6,
title = "Antiplatelet Medications: Old and Emerging Therapies",
abstract = "Antiplatelet medications have been proven to enhance outcomes in patients with cardiovascular disease. The ideal platelet inhibitor would be quick and reversible and would have universal response, an excellent safety profile, and proven benefit. Currently available antiplatelet medications have been demonstrated to have variable patient response. In light of this medication resistance, emerging therapies to inhibit platelet aggregation are under investigation. We review the currently available antiplatelet medications and the current state of these emerging therapies.",
author = "Stone, {William M.} and Sailendra Naidu and Alyssa Chapital and Money, {Samuel R.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.avsg.2009.03.008",
language = "English (US)",
volume = "24",
pages = "140--148",
journal = "Annals of Vascular Surgery",
issn = "0890-5096",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Antiplatelet Medications

T2 - Old and Emerging Therapies

AU - Stone, William M.

AU - Naidu, Sailendra

AU - Chapital, Alyssa

AU - Money, Samuel R.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Antiplatelet medications have been proven to enhance outcomes in patients with cardiovascular disease. The ideal platelet inhibitor would be quick and reversible and would have universal response, an excellent safety profile, and proven benefit. Currently available antiplatelet medications have been demonstrated to have variable patient response. In light of this medication resistance, emerging therapies to inhibit platelet aggregation are under investigation. We review the currently available antiplatelet medications and the current state of these emerging therapies.

AB - Antiplatelet medications have been proven to enhance outcomes in patients with cardiovascular disease. The ideal platelet inhibitor would be quick and reversible and would have universal response, an excellent safety profile, and proven benefit. Currently available antiplatelet medications have been demonstrated to have variable patient response. In light of this medication resistance, emerging therapies to inhibit platelet aggregation are under investigation. We review the currently available antiplatelet medications and the current state of these emerging therapies.

UR - http://www.scopus.com/inward/record.url?scp=72249086991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249086991&partnerID=8YFLogxK

U2 - 10.1016/j.avsg.2009.03.008

DO - 10.1016/j.avsg.2009.03.008

M3 - Review article

VL - 24

SP - 140

EP - 148

JO - Annals of Vascular Surgery

JF - Annals of Vascular Surgery

SN - 0890-5096

IS - 1

ER -